Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation — Wallis C. Y. Lau (2022) | RDL Network
Steven Deitelzweig, Allison Keshishian, Amiee Kang, Amol D. Dhamane, Xuemei Luo, Xiaoyan Li, Neeraja Balachander, Lisa Rosenblatt, Jack Mardekian, Xianying Pan, Manuela Di Fusco, Alessandra Bassalobre García, Hüseyin Yüce, Professor Gregory Lip
Wallis C. Y. Lau, Ching‐Lung Cheung, Kenneth K. C. Man, Esther W. Chan, Chor‐Wing Sing, Professor Gregory Lip, Chung‐Wah Siu, Joanne K.Y. Lam, Alan C.H. Lee, Ian Chi Kei Wong
Discussion(0)
No comments yet. Be the first to comment.